View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 10, 2018

Deals this week: Pharmaxis, Almirall, Cipla Quality Chemical Industries

Pharmaxis has raised A$24m ($17.74m) in two tranches through a private placement of 73.8 million shares priced at A$0.325 ($0.24) a share.

Pharmaxis has raised A$24m ($17.74m) in two tranches through a private placement of 73.8 million shares priced at A$0.325 ($0.24) a share.

The company has also received commitment from UK-based healthcare and life science company Arix to invest A$14.2m ($10.5m) in the company. Arix will gain 11.1% interest in Pharmaxis post approval from shareholders.

Based in the US, Pharmaxis is a pharmaceutical research company engaged in the development of therapies for the treatment of inflammatory and fibrotic diseases.

The company plans to use the funds to strengthen its balance sheet and towards clinical development of lysyl oxidase 2 inhibitors (LOXL2).

Almirall has signed an agreement to purchase five acne and dermatoses brands from Allergan for a cash consideration of $650m.

Almirall will acquire Allergan’s Aczone®, Tazorac®, Azelex®, Cordran® Tape, and Seysara, as per the agreement.

Based in Spain, Almirall is a manufacturer of innovative pharmaceuticals, while Allergan is a pharmaceutical drugs manufacturer based in Ireland.

The transaction will enable Almirall to expand its footprint in the US, as well as enhance its dermatological products portfolio.

Cipla Quality Chemical Industries plans to raise funds through an initial public offering (IPO) of shares.

Each shareholder of the company will sell a minority of their stake in the IPO to enable free float and liquidity.

Based in Uganda, Cipla Quality Chemical Industries is a subsidiary of Cipla and a developer of anti-retrovirals and hepatitis B medicines.

Renaissance Capital has been appointed as the lead transaction adviser and book runner to the company for the offering.

“Almirall has signed an agreement to purchase five acne and dermatoses brands from Allergan for a cash consideration of $650m.”

Bluebird Bio has collaborated with Regeneron for the discovery, development and commercialisation of novel cell therapies for cancer.

The collaboration will leverage Regeneron’s VelociSuite platform technologies for the discovery and characterisation of human antibodies and T-cell receptors.

The partnership with Regeneron will be a complementary addition to Bluebird’s immuno-oncology development portfolio, which includes CAR T and T-cell receptor (TCR) clinical programmes.

Bluebird Bio is a clinical-stage biotechnology company that develops novel gene therapies, while Regeneron is a biotechnology company that provides innovative medicines for people with serious diseases.

Both companies involved in the transaction are based in the US.

Glenmark Pharmaceuticals and Harbour BioMed have signed a partnership agreement for the development and commercialisation of the former’s immuno-oncology candidate GBR 1302 in Greater China.

GBR 1302 is a bispecific antibody that targets HER2 and CD3 tumours in patients, who have been tested positive for HER2 protein.

The collaboration is part of Harbour BioMed’s strategy to leverage its clinical development expertise by in-licensing novel clinical stage assets.

The partnership with Glenmark will be a complementary addition to Harbour BioMed’s innovative antibody-based therapeutics portfolio.

Based in India, Glenmark is a manufacturer of innovative pharmaceuticals, while Harbour BioMed is a China-based biopharmaceutical company engaged in the discovery and development of novel therapeutics for oncology and immunological disorders.

PDL BioPharma has completed the purchase of a 50% stake in the royalty rights and milestones of Depomed’s Type 2 diabetes products for $20m.

Depomed will receive an initial payment of $10m from PDL, as per the agreement. PDL will pay $10m in addition if the target company meets certain conditions specified in the agreement.

Products acquired by PDL from Depomed include Glumetza®, Jentadueto XR®, Invokamet XR® and Synjardy XR®.

PDL BioPharma is a biopharmaceutical company based in the US, while Depomed, also based in the US, is a pharmaceutical company engaged in the development and commercialisation of products for neurology and central nervous system disorders.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology